Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Invested Capital (2016 - 2026)

Standard Biotools has reported Invested Capital over the past 16 years, most recently at $424.3 million for Q4 2025.

  • Quarterly Invested Capital fell 10.05% to $424.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $424.3 million through Dec 2025, down 10.05% year-over-year, with the annual reading at $424.3 million for FY2025, 10.05% down from the prior year.
  • Invested Capital was $424.3 million for Q4 2025 at Standard Biotools, up from $399.7 million in the prior quarter.
  • Over five years, Invested Capital peaked at $577.3 million in Q1 2024 and troughed at -$126.7 million in Q3 2023.
  • The 5-year median for Invested Capital is $116.2 million (2021), against an average of $194.2 million.
  • Year-over-year, Invested Capital plummeted 536.77% in 2023 and then soared 1273.7% in 2024.
  • A 5-year view of Invested Capital shows it stood at $148.8 million in 2021, then plummeted by 111.14% to -$16.6 million in 2022, then plummeted by 464.23% to -$93.5 million in 2023, then skyrocketed by 604.4% to $471.7 million in 2024, then dropped by 10.05% to $424.3 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Invested Capital are $424.3 million (Q4 2025), $399.7 million (Q3 2025), and $424.5 million (Q2 2025).